Nuveen Asset Management LLC cut its holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 50.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 56,846 shares of the company's stock after selling 58,276 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.09% of Pulse Biosciences worth $990,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in PLSE. Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after acquiring an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Pulse Biosciences during the fourth quarter worth approximately $44,000. Caisse Des Depots ET Consignations acquired a new position in shares of Pulse Biosciences during the fourth quarter worth approximately $95,000. Farther Finance Advisors LLC grew its stake in shares of Pulse Biosciences by 44.4% during the fourth quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock valued at $126,000 after purchasing an additional 2,220 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Pulse Biosciences in the fourth quarter valued at approximately $193,000. 76.95% of the stock is owned by institutional investors.
Pulse Biosciences Stock Up 4.8%
Shares of NASDAQ PLSE traded up $0.78 during midday trading on Friday, hitting $17.10. The stock had a trading volume of 158,354 shares, compared to its average volume of 186,798. Pulse Biosciences, Inc. has a fifty-two week low of $9.70 and a fifty-two week high of $25.00. The company's 50-day simple moving average is $16.82 and its 200 day simple moving average is $17.98.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Pulse Biosciences to a "sell" rating in a research report on Monday, March 31st.
View Our Latest Research Report on PLSE
Pulse Biosciences Profile
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
